-
Something wrong with this record ?
ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients
ADJ. Pearson, C. Rossig, G. Lesa, SJ. Diede, S. Weiner, J. Anderson, J. Gray, B. Geoerger, V. Minard-Colin, LV. Marshall, M. Smith, P. Sondel, M. Bajars, C. Baldazzi, E. Barry, S. Blackman, P. Blanc, R. Capdeville, H. Caron, PD. Cole, JC....
Language English Country Great Britain
Document type Journal Article
- MeSH
- CTLA-4 Antigen antagonists & inhibitors MeSH
- B7-H1 Antigen antagonists & inhibitors MeSH
- Child MeSH
- Immunotherapy methods MeSH
- Drug Therapy, Combination MeSH
- Humans MeSH
- Neoplasms drug therapy pathology MeSH
- Needs Assessment * MeSH
- Patient Care Planning organization & administration MeSH
- Prognosis MeSH
- Antineoplastic Agents therapeutic use MeSH
- Government Agencies organization & administration MeSH
- Drug Development * MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
The third multistakeholder Paediatric Strategy Forum organised by ACCELERATE and the European Medicines Agency focused on immune checkpoint inhibitors for use in combination therapy in children and adolescents. As immune checkpoint inhibitors, both as monotherapy and in combinations have shown impressive success in some adult malignancies and early phase trials in children of single agent checkpoint inhibitors have now been completed, it seemed an appropriate time to consider opportunities for paediatric studies of checkpoint inhibitors used in combination. Among paediatric patients, early clinical studies of checkpoint inhibitors used as monotherapy have demonstrated a high rate of activity, including complete responses, in Hodgkin lymphoma and hypermutant paediatric tumours. Activity has been very limited, however, in more common malignancies of childhood and adolescence. Furthermore, apart from tumour mutational burden, no other predictive biomarker for monotherapy activity in paediatric tumours has been identified. Based on these observations, there is collective agreement that there is no scientific rationale for children to be enrolled in new monotherapy trials of additional checkpoint inhibitors with the same mechanism of action of agents already studied (e.g. anti-PD1, anti-PDL1 anti-CTLA-4) unless additional scientific knowledge supporting a different approach becomes available. This shared perspective, based on scientific evidence and supported by paediatric oncology cooperative groups, should inform companies on whether a paediatric development plan is justified. This could then be proposed to regulators through the available regulatory tools. Generally, an academic-industry consensus on the scientific merits of a proposal before submission of a paediatric investigational plan would be of great benefit to determine which studies have the highest probability of generating new insights. There is already a rationale for the evaluation of combinations of checkpoint inhibitors with other agents in paediatric Hodgkin lymphoma and hypermutated tumours in view of the activity shown as single agents. In paediatric tumours where no single agent activity has been observed in multiple clinical trials of anti-PD1, anti-PDL1 and anti-CTLA-4 agents as monotherapy, combinations of checkpoint inhibitors with other treatment modalities should be explored when a scientific rationale indicates that they could be efficacious in paediatric cancers and not because these combinations are being evaluated in adults. Immunotherapy in the form of engineered proteins (e.g. monoclonal antibodies and T cell engaging agents) and cellular products (e.g. CAR T cells) has great therapeutic potential for benefit in paediatric cancer. The major challenge for developing checkpoint inhibitors for paediatric cancers is the lack of neoantigens (based on mutations) and corresponding antigen-specific T cells. Progress critically depends on understanding the immune macroenvironment and microenvironment and the ability of the adaptive immune system to recognise paediatric cancers in the absence of high neoantigen burden. Future clinical studies of checkpoint inhibitors in children need to build upon strong biological hypotheses that take into account the distinctive immunobiology of childhood cancers in comparison to that of checkpoint inhibitor responsive adult cancers.
Boehringer Ingelheimm Pharma GmbH Germany
Children's Cause for Cancer Advocacy USA
Food and Drug Administration USA
Gustave Roussy Cancer Centre France
Hospital for Sick Children Toronto Canada
Imagine for Margo Unite2Cure France
Merck and Co Inc Kenilworth NJ USA
National Institutes of Health USA
Royal Marsden Hospital and Institute of Cancer Research UK
Rutgers Cancer Institute of New Jersey USA
Southampton University NHS Trust UK
The University of Wisconsin Madison WI USA
UCL Great Ormond Street Institute of Child Health UK
Universitair Ziekenhuis Antwerpen Belgium
University Children´s Hospital Muenster Pediatric Hematology and Oncology Germany
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025167
- 003
- CZ-PrNML
- 005
- 20201222153724.0
- 007
- ta
- 008
- 201125s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejca.2019.12.029 $2 doi
- 035 __
- $a (PubMed)31986450
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Pearson, Andrew D J $u ACCELERATE, Europe. Electronic address: andy1pearson@btinternet.com.
- 245 10
- $a ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients / $c ADJ. Pearson, C. Rossig, G. Lesa, SJ. Diede, S. Weiner, J. Anderson, J. Gray, B. Geoerger, V. Minard-Colin, LV. Marshall, M. Smith, P. Sondel, M. Bajars, C. Baldazzi, E. Barry, S. Blackman, P. Blanc, R. Capdeville, H. Caron, PD. Cole, JC. Jiménez, P. Demolis, M. Donoghue, M. Elgadi, T. Gajewski, S. Galluzzo, R. Ilaria, A. Jenkner, D. Karres, M. Kieran, F. Ligas, I. Lowy, M. Meyers, C. Oprea, VGR. Peddareddigari, J. Sterba, PK. Stockman, P. Suenaert, U. Tabori, C. van Tilburg, T. Yancey, B. Weigel, K. Norga, G. Reaman, G. Vassal,
- 520 9_
- $a The third multistakeholder Paediatric Strategy Forum organised by ACCELERATE and the European Medicines Agency focused on immune checkpoint inhibitors for use in combination therapy in children and adolescents. As immune checkpoint inhibitors, both as monotherapy and in combinations have shown impressive success in some adult malignancies and early phase trials in children of single agent checkpoint inhibitors have now been completed, it seemed an appropriate time to consider opportunities for paediatric studies of checkpoint inhibitors used in combination. Among paediatric patients, early clinical studies of checkpoint inhibitors used as monotherapy have demonstrated a high rate of activity, including complete responses, in Hodgkin lymphoma and hypermutant paediatric tumours. Activity has been very limited, however, in more common malignancies of childhood and adolescence. Furthermore, apart from tumour mutational burden, no other predictive biomarker for monotherapy activity in paediatric tumours has been identified. Based on these observations, there is collective agreement that there is no scientific rationale for children to be enrolled in new monotherapy trials of additional checkpoint inhibitors with the same mechanism of action of agents already studied (e.g. anti-PD1, anti-PDL1 anti-CTLA-4) unless additional scientific knowledge supporting a different approach becomes available. This shared perspective, based on scientific evidence and supported by paediatric oncology cooperative groups, should inform companies on whether a paediatric development plan is justified. This could then be proposed to regulators through the available regulatory tools. Generally, an academic-industry consensus on the scientific merits of a proposal before submission of a paediatric investigational plan would be of great benefit to determine which studies have the highest probability of generating new insights. There is already a rationale for the evaluation of combinations of checkpoint inhibitors with other agents in paediatric Hodgkin lymphoma and hypermutated tumours in view of the activity shown as single agents. In paediatric tumours where no single agent activity has been observed in multiple clinical trials of anti-PD1, anti-PDL1 and anti-CTLA-4 agents as monotherapy, combinations of checkpoint inhibitors with other treatment modalities should be explored when a scientific rationale indicates that they could be efficacious in paediatric cancers and not because these combinations are being evaluated in adults. Immunotherapy in the form of engineered proteins (e.g. monoclonal antibodies and T cell engaging agents) and cellular products (e.g. CAR T cells) has great therapeutic potential for benefit in paediatric cancer. The major challenge for developing checkpoint inhibitors for paediatric cancers is the lack of neoantigens (based on mutations) and corresponding antigen-specific T cells. Progress critically depends on understanding the immune macroenvironment and microenvironment and the ability of the adaptive immune system to recognise paediatric cancers in the absence of high neoantigen burden. Future clinical studies of checkpoint inhibitors in children need to build upon strong biological hypotheses that take into account the distinctive immunobiology of childhood cancers in comparison to that of checkpoint inhibitor responsive adult cancers.
- 650 _2
- $a protinádorové látky $x terapeutické užití $7 D000970
- 650 _2
- $a antigeny CD274 $x antagonisté a inhibitory $7 D060890
- 650 _2
- $a antigen CTLA-4 $x antagonisté a inhibitory $7 D060908
- 650 _2
- $a dítě $7 D002648
- 650 12
- $a vyvíjení léků $7 D000076722
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 _2
- $a vládní organizace $x organizace a řízení $7 D006077
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunoterapie $x metody $7 D007167
- 650 12
- $a odhad potřeb $7 D020380
- 650 _2
- $a nádory $x farmakoterapie $x patologie $7 D009369
- 650 _2
- $a plánování péče o pacienty $x organizace a řízení $7 D010347
- 650 _2
- $a prognóza $7 D011379
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Rossig, Claudia $u University Children´s Hospital Muenster, Pediatric Hematology and Oncology, Germany.
- 700 1_
- $a Lesa, Giovanni $u Paediatric Medicines Office, Product Development Scientific Support Department, European Medicines Agency, Amsterdam, the Netherlands.
- 700 1_
- $a Diede, Scott J $u Merck & Co., Inc., Kenilworth, NJ, USA.
- 700 1_
- $a Weiner, Susan $u Children's Cause for Cancer Advocacy, USA.
- 700 1_
- $a Anderson, John $u UCL Great Ormond Street Institute of Child Health, UK.
- 700 1_
- $a Gray, Juliet $u Southampton University NHS Trust, UK.
- 700 1_
- $a Geoerger, Birgit $u Gustave Roussy Cancer Centre, France.
- 700 1_
- $a Minard-Colin, Veronique $u Gustave Roussy Cancer Centre, France.
- 700 1_
- $a Marshall, Lynley V $u Royal Marsden Hospital & Institute of Cancer Research, UK.
- 700 1_
- $a Smith, Malcolm $u National Institutes of Health, USA.
- 700 1_
- $a Sondel, Paul $u The University of Wisconsin, Madison WI, USA.
- 700 1_
- $a Bajars, Marcis $u EMD Serono, USA.
- 700 1_
- $a Baldazzi, Claudia $u Tesaro, USA.
- 700 1_
- $a Barry, Elly $u Pfizer, USA.
- 700 1_
- $a Blackman, Sam $u ACCELERATE, Europe.
- 700 1_
- $a Blanc, Patricia $u Imagine for Margo, Unite2Cure, France.
- 700 1_
- $a Capdeville, Renaud $u Novartis, Switzerland.
- 700 1_
- $a Caron, Hubert $u Roche, Switzerland.
- 700 1_
- $a Cole, Peter D $u Rutgers Cancer Institute of New Jersey, USA.
- 700 1_
- $a Jiménez, Jorge Camarero $u Agencia Espanola de Medicamentos y Productos Sanitarios and European Medicines Agency, Committee for Medicinal Products for Human Use, Amsterdam, the Netherlands.
- 700 1_
- $a Demolis, Pierre $u Agence Nationale de Sécurité du Médicament et des Produits de Santé and European Medicines Agency, Scientific Advice Working Party and Oncology Working Party, Amsterdam, the Netherlands.
- 700 1_
- $a Donoghue, Martha $u Food and Drug Administration, USA.
- 700 1_
- $a Elgadi, Mabrouck $u Boehringer-Ingelheimm Pharma GmbH, Germany.
- 700 1_
- $a Gajewski, Thomas $u University of Chicago, USA.
- 700 1_
- $a Galluzzo, Sara $u Agenzia Italiana del Farmaco and European Medicines Agency, Paediatric Committee, Amsterdam, the Netherlands.
- 700 1_
- $a Ilaria, Robert $u Celgene, USA.
- 700 1_
- $a Jenkner, Alessandro $u Ospedale Pediatrico Bambino Gesù and European Medicines Agency, Paediatric Committee, Amsterdam, the Netherlands.
- 700 1_
- $a Karres, Dominik $u Paediatric Medicines Office, Product Development Scientific Support Department, European Medicines Agency, Amsterdam, the Netherlands.
- 700 1_
- $a Kieran, Mark $u BMS, USA.
- 700 1_
- $a Ligas, Franca $u Paediatric Medicines Office, Product Development Scientific Support Department, European Medicines Agency, Amsterdam, the Netherlands.
- 700 1_
- $a Lowy, Israel $u Regeneron, USA.
- 700 1_
- $a Meyers, Michael $u Syndax Pharmaceuticals, USA.
- 700 1_
- $a Oprea, Corina $u Sanofi, France.
- 700 1_
- $a Peddareddigari, Vijay G R $u Autolus, UK.
- 700 1_
- $a Sterba, Jaroslav $u University Hospital Brno and European Medicines Agency, Paediatric Committee, Amsterdam, the Netherlands.
- 700 1_
- $a Stockman, Paul K $u AstraZeneca, UK.
- 700 1_
- $a Suenaert, Peter $u Immunicum AB, Sweden.
- 700 1_
- $a Tabori, Uri $u Hospital for Sick Children, Toronto, Canada.
- 700 1_
- $a van Tilburg, Cornelis $u KiTZ Clinical Trial Unit, Hopp Children's Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Heidelberg, Germany.
- 700 1_
- $a Yancey, Todd $u Beigene, China.
- 700 1_
- $a Weigel, Brenda $u University of Minnesota, USA.
- 700 1_
- $a Norga, Koenraad $u Universitair Ziekenhuis Antwerpen, Belgium.
- 700 1_
- $a Reaman, Gregory $u Food and Drug Administration, USA.
- 700 1_
- $a Vassal, Gilles $u Gustave Roussy Cancer Centre, France.
- 773 0_
- $w MED00009626 $t European journal of cancer (Oxford, England : 1990) $x 1879-0852 $g Roč. 127, č. - (2020), s. 52-66
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31986450 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222153720 $b ABA008
- 999 __
- $a ok $b bmc $g 1599312 $s 1115853
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 127 $c - $d 52-66 $e 20200124 $i 1879-0852 $m European journal of cancer $n Eur J Cancer $x MED00009626
- LZP __
- $a Pubmed-20201125
